Synlogic (SYBX) Downgraded by ValuEngine to “Strong Sell”

ValuEngine cut shares of Synlogic (NASDAQ:SYBX) from a sell rating to a strong sell rating in a research note issued to investors on Friday morning.

A number of other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of Synlogic from a hold rating to a sell rating in a report on Wednesday. Piper Jaffray Companies assumed coverage on shares of Synlogic in a report on Monday, January 29th. They issued an overweight rating and a $16.00 target price on the stock. Finally, Wedbush assumed coverage on shares of Synlogic in a report on Monday, November 27th. They issued an outperform rating and a $20.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $18.75.

Shares of Synlogic (NASDAQ SYBX) traded down $0.02 during trading on Friday, hitting $9.80. 322,300 shares of the stock were exchanged, compared to its average volume of 189,041. The firm has a market cap of $159.92, a PE ratio of -1.04 and a beta of 2.91. Synlogic has a fifty-two week low of $8.76 and a fifty-two week high of $23.00.

Synlogic (NASDAQ:SYBX) last announced its earnings results on Monday, November 13th. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($1.16). sell-side analysts forecast that Synlogic will post -5.5 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Synlogic (SYBX) Downgraded by ValuEngine to “Strong Sell”” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at

About Synlogic

Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with's FREE daily email newsletter.

Leave a Reply